Insulin Lispro-aabc Injection
Brand names: Lyumjev Tempo Pen
Category: Endocrinology/Metabolism
FDA status: To Be Discontinued · Last FDA update: Oct 24, 2025 · First posted: Oct 24, 2025 · 1 manufacturers, 2 listed presentations
As of Oct 24, 2025, the FDA lists Insulin Lispro-aabc Injection as being discontinued. Of 2 manufacturer presentations, 2 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05) NDC 0002-8235-05 |
Eli Lilly and Co. | Not specified | A business decision was made to discontinue manufacture of the drug. |
| Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99) NDC 0002-8235-99 |
Eli Lilly and Co. | Not specified | A business decision was made to discontinue manufacture of the drug. |
Related medications in shortage
Other Endocrinology/Metabolism medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Insulin Lispro-aabc Injection (FDA data as of Oct 24, 2025). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Insulin Lispro-aabc Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/insulin-lispro-aabc-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).